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Helper T cells are stimulated to fight infections or diseases upon recognition of peptides
from antigens that are processed and presented by the proteins of Major Histocompati-
bility Complex (MHC) Class II molecules. Degradation of a full protein into small peptide
fragments is a lengthy process consisting of many steps and chaperones. Malfunctions
during any step of antigen processing could lead to the development of self-reactive T
cells or defective immune response to pathogens. Although much has been accomplished
regarding how antigens are processed and presented toT cells, many questions still remain
unanswered, preventing the design of therapeutics for direct intervention with antigen pro-
cessing. Here, we review published work on the discovery and function of a MHC class
II molecular chaperone, HLA-DO, in human, and its mouse analog H2-O, herein called
DO. While DO was originally discovered decades ago, elucidating its function has proven
challenging. DO was discovered in association with another chaperone HLA-DM (DM) but
unlike DM, its distribution is more tissue specific, and its function more subtle.
Keywords: HLA-DO, HLA-DR antigens, MHC class II antigen processing, models for HLA-DO function, HLA-DM
INTRODUCTION
Major Histocompatibility Complex (MHC) Class II molecules are
heterodimeric glycoproteins consisting of one α-chain of approx-
imately 34 kDa and one β-chain of approximately 28 kDa (1). In
general, polymorphic classical MHC class II molecules bind and
present peptide antigens. Non-classical MHC II molecules are gen-
erally non-polymorphic and serve as chaperones and accessory
proteins that assist with folding, transport, antigenic peptide load-
ing, and editing (2). An inherent difficulty in studying the MHC II
locus arose from the large genomic distances between the protein
coding regions of some alpha and beta chain pairs. When the beta
chain of the DO molecule was discovered it was originally thought
to be another member of the classical MHC II family and not an
accessory molecule, and hence was designated as Aβ2, an alterna-
tive beta chain of the existing MHC II I-A molecule (3). While the
classical β-chains were 63–69% homologous to each other, Aβ2
chain was found to have 49–56% homology to the A and E β-
chains and to the human DP, DQ, and DR β-chains. This made
the Aβ2 chain the most divergent member of the β-chain family.
Another difference between the Aβ2 gene and classical MHC II
genes was that it showed very little polymorphism. This led to the
hypothesis that Aβ2 may have a function distinct from the classical
Aβ and Eβ genes.
It took many years before the protein product of the Aβ2 gene
(at the time referred to as H2-Oβ) was finally confirmed by a
study that made a rabbit antiserum against the predicted cytoplas-
mic tail. Two-dimensional electrophoreses of immunoprecipitated
H2-Oβ indicated the presence of an α chain. H2-O was found to
be expressed only in tissue samples of B cell dependent areas and a
few sparse locations in the thymic medulla, leading to some spec-
ulation about its role in the immune system (4). The human form
of DO was discovered in the same way. This study in addition
to confirming the existence of DO in humans reported that DO
interacted stably with DM and could be co-precipitated as a com-
plex (5). It was found that the transport of DO chains out of the
ER depended upon its oligomerization with DM. The necessity of
DM for transport was supported by the poor expression of H2-O
in DM knockout mice, as in the absence of DM no DO could be
detected outside the ER. It seemed strange that DO would require a
stable interaction with DM for the sole purpose of being shuttled
to the endosomal compartment (6, 7). Recently it was reported
that the assembly of DM/DO complex depended upon a single
residue in the alpha chain, a buried Proline (alpha11) on the floor
of the putative peptide-binding groove (8). Authors demonstrated
that mutating this residue abolished all effects of DM on ER egress
and intracellular trafficking. The existence of DO in complex with
DM became a new paradigm in research on DO, leading to the
postulation that DO must be a regulator of DM functions.
TISSUE DISTRIBUTION OF HLA-DO/H2-O
Another key indicator of the biological significance of DO is its dif-
ferential tissue distribution. Unlike all other MHC II molecules,
which are fully expressed in professional Antigen Presenting Cells
(APCs), DO was originally detected only in B cells and the thymic
medulla (4). Expression of DO in B cells has been shown to vary
throughout cellular development and activation (9, 10). Imma-
ture mouse bone marrow B cells show expression of conventional
MHC II molecules as well as DM, but not DO. Only after migra-
tion to the spleen do B cells start to show the detectable levels
of DO which are maintained in all transitional B cell subsets and
even in mature cells. However, this expression level is significantly
down-regulated upon entry into germinal centers (GCs).
Further studies using human cells found that HLA-DR (DR)
and DO were expressed in thymic medullary cells (11, 12). Specif-
ically, the epithelial cells, which ring the Hassall’s corpuscles (HC)
structures, expressed high levels of DO. HCs are unique structures
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found within the thymic medulla, of varying size and morphol-
ogy, consisting of “swirls” of keratinized epithelium (13). The HC
bodies are the only sites within the human thymic medulla where
dying thymocytes are detected outside of the thymic cortex. Not
much is known about the true purpose of HCs in the human
immune system, although some studies have linked them to the
generation of regulatory T cells and autoimmune disease (14).
More recently, few studies reported some expression of DO
in certain subsets of DCs (10, 15). Most notable is the BDCA-3+
subset of human blood plasmacytoid DCs, which nearly uniformly
expresses DO (16). DO was also found to be expressed in subpop-
ulations of BDCA1+ CD11c+ DCs and tonsillar interdigitating
DCs. The expression of DO in Langerhans cells (LCs) was found
to vary greatly among donors, which diminished upon matura-
tion. In another study, CD8α+murine splenic DCs expressed more
H2-O than CD8α− DC (15). It is apparent that the up- or down-
regulation of DO is largely regulated by the immune system in
various tissues, an indication that DO contributes in a unique way
to antigen processing and presentation.
HLA-DO/H2-O FUNCTIONS OBSERVED IN VIVO
DM knockout mice produced detectable phenotypes of altered
antigen presentation (17–21). Most notable phenotype in the first
DM−/− mice was the predominant occupancy of their MHC II
(I-Ab) with CLIP peptides. H-2M−/−mice had a reduced number
of CD4+ T cells, which reacted strongly against wild-type cells
in mixed lymphocyte reaction. With DO, the story turned out to
be much more complicated. It was observed that human T cell
lines when transfected with genes for DR1, DM, and DO pre-
sented CLIP at higher levels than when DO was absent, suggesting
that DO inhibited the function of DM (22). On the contrary, B
cells from DO knockout mice expressed CLIP at similar levels
as their wild-type counterparts (23, 24). Throughout countless
experiments, the effects of DO on antigen presentation appeared
highly controversial, if detectable at all, as the in vivo results did not
match the findings in transfected cells lines (23–25). One notable
study interrogated the ability of B cells in H2-O knockout and
wild-type mice to enter the GCs (26). Given that the expression
of DO in B cells was up-regulated during maturation but down-
regulated upon the entry into GCs, the study reasoned that DO
may be affecting the ability of B cells to enter the GCs. If DO had
a measurable effect on the presentation of Class II antigens on
the cell surface, it would also affect the ability of B cells to receive
CD4+ T cell help and hence enter the GCs. To test this hypoth-
esis a 1:1 mixture of H2-O−/− and wild-type B cells specific for
the 4-hydroxy-3-nitrophenyl acetyl ligand (NP) were adoptively
transferred to B6 recipient mice. Mice were then immunized with
NP-linked chicken gamma globulin (CGG), and then the abun-
dance of H2-O−/− and wild-type B cells in the GCs were measured
20 days later. Draghi et al. (26) found that H2-O−/− cells outnum-
bered wild-type B cells by a ratio of 3 to 1. The study went to
great lengths to confirm that these results were due to enhanced
ability of H2-O−/− cells to present CGG. However, when NP-
linked ovalbumin (OVA) was used as an antigen, the effect was
reversed. This time wild-type B cells expressing DO outnumbered
the DO knockout cells in the GCs. This study demonstrated that
the effect of DO on antigen presentation could vary depending on
the antigen. When detectable, the effect of DO on the presentation
of two antigens that were tested was not “all-or-none,” but rather
incremental; a large portion of the B cell population was favored
over the other.
In an attempt aimed at discerning the effects of DO, Yi et al.
overexpressed human HLA-DO genes in CD11c+ DCs of non-
obese diabetic (NOD) mice (27). The results were astonishing, as
HLA-DO transgenic mice (NOD.DO) did not develop diabetes
even after 50 weeks. However, when NOD.DO T cells were trans-
ferred into NOD.SCID hosts lacking T and B cells, mice developed
diabetes. More importantly, NOD.DO mice developed diabetes
upon receiving T cells from diabetic NOD donors, indicating
that DO overexpression in DCs did not prevent diabetogenic T
cells from forming but prevented their pathogenic effects. A more
recent study reported that H2-O−/− mice could spontaneously
develop high titers of antinuclear antibodies (ANAs) indicative
of a mouse model of autoimmune systemic lupus erythematosus
(28). The mice did not, however, develop an autoimmune pathol-
ogy associated with lupus, and H2-O−/− mice showed a reduced
capacity to present exogenous antigens to the helper T cells, adding
to the contradictory nature of DO.
HLA-DM/HLA-DO COMPLEX CRYSTAL STRUCTURE
To avoid the complexities associated with the in vivo experiments,
a need for direct biochemical and structural studies became evi-
dent. A breakthrough was made when a 3-D crystal structure of the
DM/DO complex was solved (29). The study showed that binding
of DM to DO reduced the ability of DM to enhance binding of
a variant of HA-306-318 peptide of influenza of Texas77 to DR1,
and to dissociate CLIP. Authors demonstrated that upon binding
to DO, the conformation of DM does not change significantly, as
compared to unbound DM (30, 31). These findings were further
enforced with the recent crystal structure of the DM-DR complex
(32, 33). The structure of DO in complex with DM superimposed
well with the structure of DR1 (34). Altogether, the structural evi-
dence suggests that DO may mimic the MHC class II molecules in
binding to DM, possibly to compete with MHC class II interacting
with DM. It is important to note that even though the interac-
tion between DM and DO is stable, the interaction between DM
and DR is transient and was only stabilized under highly stringent
conditions, which included generation of peptide-receptive DR
molecules (35–37). While the interface of DM interacting with
DR might be the same as that of DM interacting with DO, the
magnitude and the functional specificity of this interaction are
completely different. Mutational analysis that mapped residues
important to the interaction of DM with DR1 showed that the
amino acid residues known to disturb the DM/DR interaction
(38) mapped almost entirely to the DM/DO interface (39). How-
ever, although DM mutants, DM βHis141 and βSer142, inhibited
the ability of DO to suppress DM, they had no effect on the ability
of DM to facilitate peptide binding to DR, presumably because of
differences in the nature of the two interactions (33).
MECHANISMS OF HLA-DO FUNCTION
While many different models have been put forward to explain
the mechanism of DO function, the most dominant one is that
of DO being an inhibitor of DM. With the release of the DM/DO
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FIGURE 1 | A model for the effects of HLA-DO on antigen
presentation. Starting from a CLIP-bound DM-sensitive conformation
(conformation 1), DR interacts with DM (conformation 1’ ), and a
peptide-receptive open conformation is generated (conformation 2). An
open conformation can also be induced by DM interacting with empty DR
(conformation 6’ ). DO or DM/DO complexes interact with
peptide-receptive DR molecules and stabilize an overly receptive
conformation (conformation 3). In the pool of available peptides those that
form DM-sensitive complexes with DR do not get a chance to stabilize in
the groove. On the contrary, those peptides that form DM-resistant
complexes undergo conformational changes and form DR-compact dimers
(conformation 4), which are shuttled to the cell membrane (conformation
5 ). If DR-receptive (conformation 2) does not find a peptide to bind it
converts to a closed conformation (conformation 6 ).
crystal structure, this model has gained even more support. The
inhibition of DM by DO was observed in some of the earliest bio-
chemical assays performed with DM/DO complexes copurified
from cells (22, 40), as well as recombinant soluble DO within pH
ranges of 5.5–6, but was absent at the pH of 4.5–5.0 (23). Authors
proposed that DO was necessary to limit the pH interval in which
DM is fully active. In contrast, other studies did not confirm a pH
dependent effect on the inhibitory function of DO (39, 41).
Alternative models were developed to explain DO function.
One such model came from Kropshofer et al. who reported that
DM/DO complexes purified from the human spleen had a positive
effect on the loading of HA peptide onto DR4, DR1, and DR3 mol-
ecules as compared to purified DM alone (42). More importantly,
the study showed that the enhancement of HA peptide binding
occurred even when soluble recombinant DO was used instead of
the cell purified molecules. Although this effect of DO was exactly
the opposite of those observed previously, it was also pH depen-
dent with DO performing best in the same pH range as described
before. But the best insights into the function of DO came from
peptide elution experiments from DR4, where addition of DO
changed the repertoire of the eluted peptides as compared to DM
only (42). In the presence of DM, four out of eight peptides were
predominantly loaded onto the DR4 molecules, but when both
DM and DO were present, a different set of four out of eight pep-
tides was detected. These findings suggested that just like DM, DO
can up- or down-modulate presentation of certain peptides.
Another attempt toward understanding the role of DO in pep-
tide selection was recently published (43). In this study authors
found differences in how DO affected loading of different peptides
onto DR1. A type II collagen-derived peptide and a low-affinity HA
peptide variant were inhibited in their binding to DR1, whereas
the bindings of the immunodominant peptides from two differ-
ent strains of influenza were enhanced by the addition of DO (44).
Authors found that DO only affected the association of peptides to
DR1 and had no effect on their dissociation. Moreover, the differ-
ential effects of DO on peptide association directly correlated with
DR1 peptide complex sensitivity to DM-mediated dissociation.
Peptides that formed complexes with DR1 and were sensitive to
DM-mediated dissociation were inhibited by DO, whereas those
peptide complexes that were resistant to DM-mediated dissoci-
ation were enhanced by DO. Importantly, the effect of DO was
dominant over the effects of DM. Adding to the complexity was
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the observation that the effect of DO on peptide binding occurred
even in the absence of DM. Since DO only affected the association
of peptide binding, and that DO is always in complex with DM in
the antigen processing compartments, authors theorized that DO
might only affect certain open conformations of DR molecules
generated by DM. A signature of MHC class II molecules is their
uncommon tendency to adopt different conformations based on
binding to peptides of different sequences and/or conformational
states associated with transient interactions with accessory mole-
cules. It follows that for MHC II molecular interactions with DM
and the following peptide selections all depend on the recognition
of different conformations of the molecules (35–37).
To test the model that DO might only affect certain open con-
formations of DR molecules, Poluektov et al. examined the effects
of DO on peptide binding to a mutant DR1 molecule that is always
in an open peptide-receptive conformation (45–47) independent
of DM. The mutant molecule although resistant to recognition by
DM, was inhibited from binding to a DM-sensitive HA peptide
variant in the presence of DO. Considering that the mutant DR1
molecule is unable to adopt a closed conformation and is fixed in
its receptive state, it is likely that DO forces the DR1 molecule into
yet another conformation that preferentially binds DM-resistant
peptides, which can generate a closed compact folded MHC II. As
such the effects of DO would be to enhance the binding of DM-
resistant peptides while diminishing binding of the DM-sensitive
peptides.
Considering the data above, Poluektov et al. proposed a model
for the mechanism of DO in the context of DM and DR (Figure 1).
Authors proposed that DO works together with DM to edit the
peptide repertoire presented by MHC II. In this model DM is nec-
essary to generate a peptide-receptive conformation in DR, which
is then acted upon by DO. DM thereby provides the first round of
peptide editing and DO selects from the peptides favored by DM
by promoting the binding of DM-resistant peptides while inhibit-
ing the binding of DM-sensitive ones. To verify the model, authors
showed that DO forms a stable complex with a peptide-receptive
DR molecule using surface plasmon resonance. In addition,
co-expressed recombinant DM/DO had the same effects on
peptide binding as DO alone, even when the DM/DO complexes
were used in conjunction with free DM. Based on the activity of
the DM/DO complex reported by Poluektov et al. the active site
of DO is likely located outside the interface between DM and DO,
and hence DM/DO has the same functionality as that of DO alone.
CONCLUSION
While the true mechanism of DO still remains largely unknown,
based on the data available to us we can speculate on its role in
the immune system. We know that DO is a highly evolutionarily
conserved molecule (48–50), but unlike the classical MHC genes,
DO is not polymorphic. This indicates that DO is in fact an impor-
tant gene that provides some evolutionary benefits to its host. It
has even been reported that a point mutation in the human HLA-
DOα gene was linked to a susceptibility to rheumatoid arthritis
(RA) (51), suggesting that the effects of DO are far reaching.
While the model that describes DO solely as an inhibitor of
DM by preventing its major role in the selection of immunodom-
inant epitopes (44, 52) fits some of the observed effects of DO
(53), it does not provide an adequate explanation for why DO has
been evolutionary so conserved nor does it explain the variable
expression of DO among different subsets of professional APCs,
and at different stages of cellular differentiation (8, 54). A more
likely explanation is that DO has some critical role in fine tuning,
or improving the antigenic peptide repertoire selection in collab-
oration with DM: the expression of DO in B cells could easily be
explained by the need to limit the number of long-lived memory
T cells developed against different antigens (55–57), and in the
thymus, DO contributes to the presentation of a repertoire that is
most contrived yet effective permitting deletion of all possible self-
reactive T cells (58). DO is potentially a new lever that could help to
control the antigenic repertoires generated by the immune system.
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